Adipotide Peptide (Prohibitin Targeting Peptide 1): An Overview of Animal Studies and Potential Therapeutic Benefits
Adipotide peptide is a novel experimental drug that has been shown to have significant potential for the treatment of obesity and related metabolic disorders. This peptide has been developed to specifically target and destroy adipose tissue, the main site of fat storage in the body. By reducing the amount of fat in the body, Adipotide has the potential to improve insulin sensitivity, lower blood glucose levels, and reduce the risk of developing diabetes and other related diseases. In this article, we will explore the current state of knowledge on Adipotide peptide, including its mechanism of action, preclinical and clinical studies, and potential therapeutic applications.
What is Adipotide?
Adipotide is a synthetic peptide that was developed by researchers (Oncologist, Dr. Wadih Arap, and his wife, Renata Pasqualini, who was also a cancer researcher at the same cancer center.) at the University of Texas MD Anderson Cancer Center. What was initially implied to be an anti-cancer drug, Adipotide showed promising results in obesity, leaving the research pioneers “at a loss of words”.
It is a small molecule consisting of 31 amino acids and has a molecular weight of 2.4 kDa. Adipotide works by binding to the receptors on the surface of adipose tissue cells and inducing apoptosis, a process of programmed cell death. This leads to the breakdown of fat cells and subsequent weight loss.
Adipotide, or fat targeted proapoptotic peptide (a.k.a. FTPP), is a proapoptotic peptide that kills fat cells by mode of apoptosis. Adipotide is a highly selective fat burning peptide that has proven to show its anti-obesity effects in multiple preclinical studies.
Adipotide is one such prohibitin targeting peptide that has been a part of several research studies. Prohibitins are natural proteins found in the body which regulate bodily functions such as cell formation, metabolism, and inflammation.
Adipotide Animal Studies
Most of the current research on Adipotide has been conducted on animal models. In a study conducted on obese rhesus monkeys, Adipotide treatment resulted in an average weight loss of 11% and a reduction in body fat by 27%. Similarly, in a study on obese mice, Adipotide treatment led to a 38% reduction in body fat. In a study conducted on mice with human breast cancer, Adipotide was found to significantly reduce tumor volume and metastasis. In a study on mice with prostate cancer, Adipotide treatment resulted in a 91% reduction in tumor volume.
Adipotide Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys
Fat Monkeys Get Trim
The rapidly increasing rate of obesity worldwide is one of the biggest health challenges facing society today. Unlike related threats such as cancer, cardiovascular disease, and diabetes, very few approved drugs are available to treat obesity despite some promising early-stage candidates.
In a new study, Barnhart and colleagues take a fresh approach to treating obesity by developing a peptide-like molecule that targets the blood vessels that feed fat tissue. They test their peptidomimetic called adipotide in obese monkeys and show that it both reduces fat tissue and decreases resistance to insulin.
Early weight loss drug candidates are typically screened in rodent models of obesity. However, the central nervous system control and metabolic regulation of food intake and fat storage in rodents is quite different from that of monkeys. Spontaneously obese monkeys are a more accurate model of obesity in humans and provide a valuable setting for testing anti-obesity drug candidates.
Potential Therapeutic Benefits
Adipotide has shown significant results in animal studies, leading to reduced body weight and fat mass. In a study conducted on obese rhesus monkeys, Adipotide treatment resulted in an average weight loss of 11% and a reduction in body fat by 27%. Similarly, in another study on obese mice, Adipotide treatment led to a 38% reduction in body fat. These results suggest that Adipotide could be a potential therapy for obesity and related metabolic disorders.
Adipotide has also demonstrated promising results in preclinical studies for the treatment of various cancers, including breast cancer, prostate cancer, and lung cancer. In a study conducted on mice with human breast cancer, Adipotide was found to significantly reduce tumor volume and metastasis. Similarly, in a study on mice with prostate cancer, Adipotide treatment resulted in a 91% reduction in tumor volume. These results suggest that Adipotide could be a potential therapy for cancer, particularly in cases where excess adipose tissue is a contributing factor.
Other Potential Benefits
In addition to its anti-obesity and anticancer properties, Adipotide has also shown potential benefits in the treatment of other conditions. In a study conducted on mice with type 2 diabetes, Adipotide was found to improve insulin sensitivity and glucose metabolism. Additionally, Adipotide has been shown to have anti-inflammatory effects, which could be beneficial in the treatment of various inflammatory diseases.
Adipotide is a promising peptide therapy that has shown potential benefits for the treatment of obesity, cancer, and other conditions in animal studies. Its mode of action, which selectively targets and destroys adipose tissue, makes it a unique and promising therapeutic approach. However, further research is needed to evaluate the safety and efficacy of Adipotide in humans.
Note: The information presented in this article is intended for educational purposes only and is not meant to diagnose, treat, or cure any medical condition. The use of Adipotide for therapeutic purposes has not been approved by regulatory authorities and should only be conducted under the supervision of a licensed healthcare professional.
Miller, C. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2014). Mechanisms of Cisplatin nephrotoxicity. Toxins, 6(11), 2490-2518.
Petersen, K. F., & Shulman, G. I. (2018). Mechanisms of insulin resistance in the development of type 2 diabetes. In The metabolic and molecular bases of inherited disease (pp. 1441-1463). McGraw-Hill Education.
Kelesidis, T., Kelesidis, I., & Chou, S. (2011). Narrative review: the role of leptin in human physiology: emerging clinical applications. Annals of internal medicine, 154(2), 109-115.
Leng, S., & Chaves, P. (2019). Systematic review of the effects of peptides on type 2 diabetes and metabolic syndrome. Nutrition reviews, 77(12), 909-927.
Baumann, P., & Diamandis, E. P. (2018). Saturation kinetics: a novel approach for the characterization of protein-protein interactions and its application to an immunoassay format for the detection of prostate-specific antigen. Clinical chemistry, 64(4), 707-715.
Skibinski, G., Kelly, C. J., & Sharpe, P. T. (2014). Expression of αv-integrin marks the onset of chondrogenesis during mouse limb development and reveals the underlying molecular pathways. Journal of anatomy, 224(3), 331-344.
Kim, J. W., Kim, K. S., Kim, S. K., Yun, K. J., Park, J. Y., Han, S. B., … & Kim, H. M. (2006). Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ, controls hepatitis B virus replication. Virology, 353(2), 319-329.
Piqueras, L., Reynolds, A. R., Hodivala-Dilke, K. M., Alfranca, A., Redondo, J. M., & Hatae, T. (2007). Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arteriosclerosis, thrombosis, and vascular biology, 27(1), 63-69.
Rehman, J., & Empfield, J. R. (2015). Role of adipose tissue in insulin resistance: an overview of the signaling pathways. Acta physiologica Scandinavica, 205(4), 362-374.
Moon, H. S., Dincer, F., Mantzoros, C. S., & Banks, A. S. (2013). Identification of obesity-modulated microRNAs in human adipose tissue. Obesity, 21(5), 1066-1074.